Public health impact and economic value of booster vaccination with Pfizer-BioNTech COVID-19 vaccine, bivalent (original and omicron BA.4/BA.5) in the United States.
Manuela di FuscoKinga MarczellElizabeth ThoburnTimothy L WiemkenJingyan YangBenjamin YarnoffPublished in: Journal of medical economics (2023)
Booster vaccination with the Pfizer-BioNTech COVID-19 Vaccine, Bivalent for the US population aged ≥5 years could generate notable public health impact and be cost-saving based on the findings of our base case analyses.
Keyphrases